ArticleDiscover oncology2026
CCDC78 is required for prostate cancer cell growth and serves as a prognostic biomarker for high-risk disease.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAs the second most common malignancy among men worldwide, prostate cancer is commonly diagnosed through PSA testing and puncture biopsy. However, these methods have limitations in risk assessment. Clinically, low-risk patients typically require only active monitoring rather than immediate intervention, whereas high-risk patients need timely treatment. Therefore, more precise biomarkers are needed to identify prostate cancer at different risk levels.
methodsDifferentially expressed genes (DEGs) between high-risk and low-risk prostate cancer samples were identified using RNA-seq. Systematic bioinformatics approaches, including WGCNA, LASSO, and Cox regression analyses, were performed to identify potential prognostic biomarkers. Time-dependent receiver operating characteristic (ROC) curves were used to evaluate the accuracy of the identified biomarkers. Additionally, GO and KEGG enrichment analyses were conducted on genes coexpressed with the prognostic biomarker. A series of siRNA-mediated knockdown experiments, including proliferation, apoptosis, colony formation, and spheroid formation assays, were performed to assess the functional roles of the prognostic biomarker in prostate cancer.
resultsRNA-seq revealed that 656 genes were upregulated and 426 genes were downregulated in high-risk prostate cancer. Using systematic bioinformatics approaches, we identified CCDC78 as a potential prognostic biomarker for high-risk prostate cancer. Time-dependent ROC curve analysis showed that the AUCs of CCDC78 were all greater than 0.7 at the 1-, 3-, and 5-year time points. GO enrichment analysis revealed that genes coexpressed with CCDC78 were mainly enriched in tumor immune-related signaling pathways. Furthermore, siRNA-mediated knockdown of CCDC78 significantly inhibited proliferation, colony formation, and spheroid formation, while inducing apoptosis in prostate cancer cells. Importantly, knockdown of CCDC78 reduced expression of the prostate cancer driver factor AR, and partially restored proliferative activity in AR-overexpressing LNCaP cells compared with wild-type cells.
conclusionsOur study is the first to reveal that CCDC78 is required for the growth of prostate cancer cells and serves as a prognostic biomarker for high-risk disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.